Pursuing the debate on the serologic criteria that define the antiphospholipid syndrome

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 8, 2008, Pages 1433-1435

  Wahl, Denis ^a,b,c,g   Thiebaugeorges, O ^d   Regnault, V ^a   Dalloul, A ^b,e   Lecompte, T ^a,b,f  

^a INSERM   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

^c Vascular Medicine   (France)

^d Maternite Regionale Universitaire   (France)

^e Unit of Cellular Therapy   (France)

^f Haematology Laboratory   (France)

^g CHU NANCY BRABOIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G; LUPUS ANTICOAGULANT;

ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LETTER; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RISK FACTOR; SCREENING TEST; SEROLOGY; STANDARDIZATION; SYSTEMIC LUPUS ERYTHEMATOSUS; VEIN THROMBOSIS;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LUPUS COAGULATION INHIBITOR; RISK FACTORS; SEROLOGIC TESTS;

EID: 47649094135     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03009.x     Document Type: Letter

References (25)

1. Galli M, Reber G, de Moerloose P, de Groot PG. Invitation to a debate on the serological criteria that define the antiphospholipid syndrome. J Thromb Haemost 2008; 6: 399-401.
2. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, De Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
3. Pengo V. A contribution to the debate on the laboratory criteria that define the antiphospholipid syndrome. J Thromb Haemost 2008; 6: 1048-9.
4. Tripodi A. More on: Criteria to define the antiphospholipid syndrome. J Thromb Haemost 2008; 6: 1049-50.
5. Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C, Clarke A, Geerts W, Forgie M, Green D, Costantini L, Yacura W, Wilson S, Gent M, Kovacs MJ. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-8.
6. APASS Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291: 576-84.
7. Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, Musial J, Baudo F, Berrettini M, Testa S, D'Angelo A, Tognoni G, Barbui T. A randomised clinical trial of high intensity warfarin vs conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3: 848-53.
8. Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L, Unalp-Arida A, Vilela V, Yazici Y, Lockshin MD. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome. Arthritis Rheum 2007; 56: 2382-91.
9. Tincani A, Allegri F, Sanmarco M, Cinquini M, Taglietti M, Balestrieri G, Koike T, Ichikawa K, Meroni P, Boffa MC. Anticardiolipin antibody assay: A methodological analysis for a better consensus in routine determinations -a cooperative project of the European Antiphospholipid Forum. Thromb Haemost 2001; 86: 575-83.
10. Naess IA, Christiansen SC, Cannegieter SC, Rosendaal FR, Hammerstroem J. A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study). J Thromb Haemost 2006; 4: 44-9.
11. Sammaritano LR. Significance of aPL IgG subclasses. Lupus 1996; 5: 436-9.
12. Reber G, Arvieux J, Comby E, Degenne D, de Moerloose P, Sanmarco M, Potron G. Multicenter evaluation of nine commercial kits for the quantification of anticardiolipin antibodies. The working group on methodologies in haemostasis from the Groupe d'Etudes sur l'Hemostase et la Thrombose. Thromb Haemost 1995; 73: 444-52.
13. Wahl DG, Guillemin F, De Maistre E, Perret C, Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus. A meta-analysis. Lupus 1997; 6: 467-73.
14. Wahl DG, Bounameaux H, de Moerloose P, Sarasin FP. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: Do the benefits outweigh the risks? A decision analysis Arch Intern Med 2000; 160: 2042-8.
15. Opatrny L, David M, Kahn SR, Shrier I, Rey E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: A metaanalysis. J Rheumatol 2006; 33: 2214-21.
16. Reber G, Schousboe I, Tincani A, Sanmarco M, Kveder T, de Moerloose P, Boffa MC, Arvieux J. Inter-laboratory variability of anti-β2-glycoprotein I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group. Thromb Haemost 2002; 88: 66-73.
17. Reber G, Tincani A, Sanmarco M, de Moerloose P, Boffa MC, European Forum on Antiphospholipid Antibodies Standardization Group. Variability of anti-beta 2 glycoprotein I antibodies measurement by commercial assays. Thromb Haemost 2005; 94: 665-72.
18. Horbach DA, van Oort E, Donders RC, Derksen RH, de Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996; 76: 916-24.
19. 2-glycoprotein I-binding antibodies in patients without systemic lupus erythematosus. Q J Med 1998; 91: 125-30.
20. Zoghlami-Rintelen C, Vormittag R, Sailer T, Lehr S, Quehenberger P, Rumpold H, Male C, Pabinger I. The presence of IgG antibodies against beta2-glycoprotein I predicts the risk of thrombosis in ptients with the lupus anticoagulant. J Thromb Haemost 2005; 3: 1160-5.
21. Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev 2005; CD002859.
22. Cavazzana A, Ruffatti A, Tonello M, Bortolati M, de Moerloose P, Reber G. An analysis of experimental conditions influencing the anti-beta2-glycoprotein I ELISA assay results. Ann NY Acad Sci 2007; 1109: 484-92.
23. Capuano F, Grasso V, Belforte L, Pallavicini L, Tincani A, Andreoli L, Bonelli F. Development of automated assays for anticardiolipin antibodies determination: Addressing antigen and standardization issues. Ann NY Acad Sci 2007; 1109: 493-502.
24. Andreoli L, Malacarne F, Ceribelli A, Kutschera I, Tincani A. Anti-cardiolipin and anti-beta2-glycoprotein I antibodies: Performance of new commercial ELISA kits. Ann NY Acad Sci 2007; 1109: 531-7.
25. Lecompte T, Wahl D, Perret-Guillaume C, Hemker HC, Lacolley P, Regnault V. Hypercoagulability resulting from opposite effects of lupus anticoagulants is predictive of thrombotic risk. Haematologica 2007; 92: 714-15.